Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV

Inclusion Criteria (Patients are eligible to be included in the study only if they meet all of the following criteria):

1. Cancer patients, age ≥ 18 years and ≤75 years, ECOG score 0-2 points, receiving cisplatin-containing doublet chemotherapy such as cisplatin + gemcitabine / albumin paclitaxel / etoposide /fluorouracil / irinotecan / temozolomide as first line treatment;

2. Life expectancy ≥ 3 months;

3. Leucocytes≥3,000/uL;

4. AST≤2.5 × upper limit of normal;

5. Bilirubin ≤1.5 × upper limit of normal;

6. Serum creatinine ≤ 1.5 × upper limit of normal.

Exclusion Criteria (Patients will be excluded if any of the following criteria is met):

1. History of CNS disease, such as brain metastases or epilepsy;

2. Use of other antipsychotic drugs (such as risperidone, quetiapine, clozapine, phenothiazine, or butyrophenone, or such treatment is under scheduling during the study) within 30 days before enrollment; long-term use of phenothiazine as an antipsychotic agent;

3. Concurrent use of pharyngeal or abdominal radiotherapy;

4. Concurrent use of quinolone antibiotics;

5. Chronic alcoholism;

6. Known hypersensitivity to olanzapine;

7. Know arrhythmia, uncontrolled congestive heart failure or acute myocardial infarction within 6 months;

8. Known uncontrolled diabetes mellitus;

9. Vomiting or retching 24 hours before chemotherapy;

10. Use of anti-emesis drugs 48 hours before chemotherapy;

11. Concurrent use of amifostine;

12. Concurrent use of drugs and the only anti-allergic choice is dexamethasone